Matthew T. Wiley, Chief Commercial Officer at BioXcel Therapeutics, Inc. (BTAI), sold 215 shares at $0.69 ($148) on 2024-09-16, disclosed to the SEC on 2024-09-17.
Scheduled sale ($148) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BTAI | SELL | 2024-06-18 | $307 | — | Filing → |
| BTAI | SELL | 2024-04-08 | $3K | — | Filing → |
| FOMX | BUY | 2019-03-06 | $101K | — | Filing → |